{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T20:49:35Z","timestamp":1760215775476},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2013,2,17]],"date-time":"2013-02-17T00:00:00Z","timestamp":1361059200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1007\/s00277-013-1703-7","type":"journal-article","created":{"date-parts":[[2013,2,16]],"date-time":"2013-02-16T08:44:18Z","timestamp":1361004258000},"page":"863-870","source":"Crossref","is-referenced-by-count":23,"title":["Efficacy and safety of deferasirox in myelodysplastic syndromes"],"prefix":"10.1007","volume":"92","author":[{"given":"Massimo","family":"Breccia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuliana","family":"Alimena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,2,17]]},"reference":[{"issue":"1","key":"1703_CR1","first-page":"71","volume":"83","author":"C Aul","year":"1998","unstructured":"Aul C, Bowen DT, Yoshida Y (1998) Pathogenesis, etiology and epidemiology of myelodysplastic syndromes. Haematologica 83(1):71\u201386","journal-title":"Haematologica"},{"key":"1703_CR2","doi-asserted-by":"crossref","unstructured":"Greenberg PL, Young NS, Gattermann N (2002) Myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program 136\u2013161","DOI":"10.1182\/asheducation-2002.1.136"},{"issue":"17","key":"1703_CR3","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1200\/JCO.2009.25.2395","volume":"28","author":"SL Goldberg","year":"2010","unstructured":"Goldberg SL, Chen E, Corral M, Guo A, Mody-Patel N, Pecora AL, Laouri M (2010) Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries. J Clin Oncol 28(17):2847\u20132852","journal-title":"J Clin Oncol"},{"issue":"6","key":"1703_CR4","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","volume":"89","author":"P Greenberg","year":"1997","unstructured":"Greenberg P, Cox C, Le Beau MM, Fenaux P, Morel P, Sanz G et al (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89(6):2079\u20132088","journal-title":"Blood"},{"key":"1703_CR5","doi-asserted-by":"crossref","unstructured":"Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sol\u00e8 F, et al (2012) Revised international prognostic scoring system (IPSS-R) for myelodysplastic syndromes. Blood 120:2454\u20132465","DOI":"10.1182\/blood-2012-03-420489"},{"issue":"1","key":"1703_CR6","doi-asserted-by":"crossref","first-page":"30","DOI":"10.6004\/jnccn.2011.0005","volume":"9","author":"PL Greenberg","year":"2011","unstructured":"Greenberg PL, Attar E, Bennett JM, Bloomfield CD, De Castro CM, Deeg HJ et al (2011) NCCN clinical practice guidelines in oncology: myelodysplastic syndromes. J Natl Compr Canc Netw 9(1):30\u201356","journal-title":"J Natl Compr Canc Netw"},{"issue":"suppl 1","key":"1703_CR7","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1016\/j.clml.2011.04.003","volume":"11","author":"T Witte de","year":"2011","unstructured":"de Witte T (2011) Allogeneic stem cell transplantation for myelodysplastic syndromes: critical for cure? Clin Lymphoma Myeloma Leuk 11(suppl 1):S46\u2013S48","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1703_CR8","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1056\/NEJM199912233412607","volume":"341","author":"NC Andrews","year":"1999","unstructured":"Andrews NC (1999) Disorders of iron metabolism. N Engl J Med 341:1986\u20131995","journal-title":"N Engl J Med"},{"issue":"5","key":"1703_CR9","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.leukres.2012.01.006","volume":"36","author":"U Platzbecker","year":"2012","unstructured":"Platzbecker U, Hofbauer LC, Ehninger G, Holig K (2012) The clinical, quality of life, and economic consequences of chronic anemia and transfusion support in patients with myelodysplastic syndromes. Leuk Res 36(5):525\u2013536","journal-title":"Leuk Res"},{"key":"1703_CR10","doi-asserted-by":"crossref","unstructured":"Cazzola M, Della Porta MG, Malcovati L (2008) Clinical relevance of anemia and transfusion iron overload in myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program 166\u2013175","DOI":"10.1182\/asheducation-2008.1.166"},{"issue":"suppl 3","key":"1703_CR11","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/S0145-2126(07)70459-9","volume":"31","author":"L Malcovati","year":"2007","unstructured":"Malcovati L (2007) Impact of transfusion dependency and secondary iron overload on the survival of patients with myelodysplastic syndromes. Leuk Res 31(suppl 3):S2\u2013S6","journal-title":"Leuk Res"},{"issue":"30","key":"1703_CR12","doi-asserted-by":"crossref","first-page":"7594","DOI":"10.1200\/JCO.2005.01.7038","volume":"23","author":"L Malcovati","year":"2005","unstructured":"Malcovati L, Porta MG, Pascutto C, Invernizzi R, Boni M, Travaglino E et al (2005) Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 23(30):7594\u20137603","journal-title":"J Clin Oncol"},{"issue":"1","key":"1703_CR13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00277-010-1091-1","volume":"90","author":"N Gattermann","year":"2011","unstructured":"Gattermann N, Rachmilewitz EA (2011) Iron overload in MDS\u2014pathophysiology, diagnosis and complications. Ann Hematol 90(1):1\u201310","journal-title":"Ann Hematol"},{"issue":"suppl 1","key":"1703_CR14","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/S0268-960X(12)70006-1","volume":"26","author":"KM Musallam","year":"2012","unstructured":"Musallam KM, Cappellini MD, Wood JC, Taher AT (2012) Iron overload in non-transfusion-dependent thalassemia: a clinical perspective. Blood Rev 26(suppl 1):16\u201319","journal-title":"Blood Rev"},{"key":"1703_CR15","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/j.1600-0609.2007.00842.x","volume":"78","author":"M Takatoku","year":"2007","unstructured":"Takatoku M, Uchiyama T, Okamato S, Kanakura Y, Sawada K, Tomonaga M et al (2007) Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity\/mortality. Eur J Haematol 78:487\u2013494","journal-title":"Eur J Haematol"},{"key":"1703_CR16","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1182\/blood-2008-01-134858","volume":"112","author":"DE Rollison","year":"2008","unstructured":"Rollison DE, Howlader N, Smith MT et al (2008) Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001\u20132004, using data from the NAACCR and SEER programs. Blood 112:45\u201352","journal-title":"Blood"},{"key":"1703_CR17","doi-asserted-by":"crossref","unstructured":"Sanz G, Nomdedeu B, Such E, Bernal T, Belkaid M, Ardanaz MT, et al (2008) Independent impact of iron overload and transfusion dependency on survival and leukemic evolution in patients with myelodysplastic syndrome. Blood 112: abst 640","DOI":"10.1182\/blood.V112.11.640.640"},{"key":"1703_CR18","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3816\/CLK.2008.n.026","volume":"2","author":"HA Leitch","year":"2008","unstructured":"Leitch HA, Leger CS, Goodman TA, Wong KK, Wong DHC, Ramadan KM et al (2008) Improved survival in patients with myelodysplastic syndrome receiving iron chelation therapy. Clin Leuk 2:205\u2013211","journal-title":"Clin Leuk"},{"key":"1703_CR19","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/j.leukres.2012.08.001","volume":"36","author":"HA Leitch","year":"2012","unstructured":"Leitch HA, Chan C, Leger CS, Foltz LM, Ramadan KM, Vickars LM (2012) Improved survival with iron chelation therapy for red blood cell transfusion dependent lower IPSS risk MDS may be more significant in patients with a non-RARS diagnosis. Leuk Res 36:1380\u20131386","journal-title":"Leuk Res"},{"key":"1703_CR20","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.leukres.2009.12.004","volume":"34","author":"C Rose","year":"2010","unstructured":"Rose C, Brechignac S, Vassilief D, Pascal L, Stamatoullas A, Guerci A et al (2010) Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicentre study by the GFM. Leuk Res 34:864\u2013870","journal-title":"Leuk Res"},{"key":"1703_CR21","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/j.1600-0609.2007.00985.x","volume":"80","author":"J Porter","year":"2008","unstructured":"Porter J, Galanello R, Saglio G, Neufeld EJ, Vichinsky E, Cappellini MD et al (2008) Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anemias to deferasirox (ICL670): a 1-yr prospective study. Eur J Haematol 80:168\u2013176","journal-title":"Eur J Haematol"},{"key":"1703_CR22","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/j.1365-2141.2007.06695.x","volume":"138","author":"J Chacko","year":"2007","unstructured":"Chacko J, Pennell DJ, Tanner MA, Hamblin TJ, Wonke B, Levy T et al (2007) Myocardial iron loading by magnetic resonance imaging T2 in good prognostic myelodysplastic syndrome patients on long-term blood transfusions. Br J Haematol 138:587\u2013593","journal-title":"Br J Haematol"},{"key":"1703_CR23","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s00277-008-0588-3","volume":"88","author":"G Metzgeroth","year":"2009","unstructured":"Metzgeroth G, Dinter D, Schultheis B, Dorn-Beineke A, Lutz K, Leismann O et al (2009) Deferasirox in MDS patients with transfusion-caused iron overload\u2014a phase II study. Ann Hematol 88:301\u2013310","journal-title":"Ann Hematol"},{"issue":"5","key":"1703_CR24","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1111\/j.1365-2362.2009.02108.x","volume":"39","author":"F Wimazal","year":"2009","unstructured":"Wimazal F, Nosslinger T, Baumgartner C, Sperr WR, Pfeilstocker M, Valent P (2009) Deferasirox induces regression of iron overload in patients with myelodysplastic syndromes. Eur J Clin Investig 39(5):406\u2013411","journal-title":"Eur J Clin Investig"},{"issue":"9","key":"1703_CR25","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.leukres.2010.03.009","volume":"34","author":"N Gattermann","year":"2010","unstructured":"Gattermann N, Finelli C, Porta MD, Fenaux P, Ganser A, Guerci-Bresler A et al (2010) Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: results from the large 1-year EPIC study. Leuk Res 34(9):1143\u20131150","journal-title":"Leuk Res"},{"issue":"3","key":"1703_CR26","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/j.1600-0609.2011.01726.x","volume":"88","author":"N Gattermann","year":"2012","unstructured":"Gattermann N, Jarish A, Schlag R, Blumenstengel K, Goebeler M, Groschek M et al (2012) Deferasirox treatment of iron-overloaded chelation-na\u00efve and prechelated patients with myelodysplastic syndromes in medical practice: results from the observational studies eXtend and eXjange. Eur J Haematol 88(3):260\u2013268","journal-title":"Eur J Haematol"},{"issue":"9","key":"1703_CR27","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1007\/s00277-012-1481-7","volume":"91","author":"M Breccia","year":"2012","unstructured":"Breccia M, Finsinger P, Loglisci G, Federico V, Santopietro M, Colafigli G et al (2012) Deferasirox treatment for myelodysplastic syndromes: \u201creal-life\u201d efficacy and safety in a single-institution patient population. Ann Hematol 91(9):1345\u20131349","journal-title":"Ann Hematol"},{"issue":"17","key":"1703_CR28","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1200\/JCO.2010.34.1222","volume":"30","author":"AF List","year":"2012","unstructured":"List AF, Baer MR, Steensma DP, Raza A, Esposito J, Martinez-Lopez N et al (2012) Deferasirox reduces serum ferritin and labile plasma iron in RBC transfusion-dependent patients with myelodysplastic syndrome. J Clin Oncol 30(17):2134\u20132139","journal-title":"J Clin Oncol"},{"key":"1703_CR29","doi-asserted-by":"crossref","unstructured":"Nolte F, Hochsmann B, Giagounidis A, Lubbert M, Platzbecker U, Haase D, et al (2013) Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload. Ann Hematol 92:191\u2013198","DOI":"10.1007\/s00277-012-1594-z"},{"issue":"9","key":"1703_CR30","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/j.leukres.2011.06.013","volume":"35","author":"F Nolte","year":"2011","unstructured":"Nolte F, Angelucci E, Beris P, Macwhannell A, Sellesiag D, Schumann C et al (2011) Clinical management of gastrointestinal disturbances in patients with myelodysplastic syndromes receiving iron chelation treatment with deferasirox. Leuk Res 35(9):1131\u20131135","journal-title":"Leuk Res"},{"issue":"5","key":"1703_CR31","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/ajh.21119","volume":"83","author":"E Vichinsky","year":"2008","unstructured":"Vichinsky E (2008) Clinical application of deferasirox: practical patient management. Am J Hematol 83(5):398\u2013402","journal-title":"Am J Hematol"},{"issue":"1","key":"1703_CR32","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1159\/000209206","volume":"121","author":"S Capalbo","year":"2009","unstructured":"Capalbo S, Spinosa G, Franzese MG, Palumbo G (2009) Early deferasirox treatment in a patient with myelodysplastic syndrome results in a long-term reduction in transfusion requirements. Acta Haematol 121(1):19\u201320","journal-title":"Acta Haematol"},{"issue":"11","key":"1703_CR33","first-page":"1626","volume":"50","author":"H Okabe","year":"2009","unstructured":"Okabe H, Suzuki T, Omori T, Mori M, Uehara E, Hatano K et al (2009) Hematopoietic recovery after administration of deferasirox for transfusional iron overload in a case of myelodysplastic syndrome. Rinsho Ketsueki 50(11):1626\u20131629","journal-title":"Rinsho Ketsueki"},{"key":"1703_CR34","doi-asserted-by":"crossref","first-page":"164045","DOI":"10.1155\/2010\/164045","volume":"2010","author":"MA Badawi","year":"2010","unstructured":"Badawi MA, Vickars LM, Chase JM, Leitch HA (2010) Red blood cell transfusion independence following the initiation of iron chelation therapy in myelodysplastic syndrome. Adv Hematol 2010:164045","journal-title":"Adv Hematol"},{"issue":"7","key":"1703_CR35","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1111\/j.1537-2995.2010.02617.x","volume":"50","author":"EN Oliva","year":"2010","unstructured":"Oliva EN, Ronco F, Marino A, Alati C, Pratico G, Nobile F (2010) Iron chelation therapy associated with improvement of hematopoiesis in transfusion-dependent patients. Transfusion 50(7):1568\u20131570","journal-title":"Transfusion"},{"key":"1703_CR36","unstructured":"Molteni A, Riva M, Speziale V, Morra E, Cappellini MD (2010) Iron-chelation therapy in MDS\/IMF patients: does it really impact on transfusion requirements? Haematologica 95 (suppl 2): abst 1410"},{"issue":"2","key":"1703_CR37","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s12185-010-0500-5","volume":"91","author":"T Nishiuchi","year":"2010","unstructured":"Nishiuchi T, Okutani Y, Fujita T, Yoshida K, Ohnishi H, Haba R (2010) Effect of iron chelator deferasirox on chronic anemia and thrombocytopenia in a transfusion-dependent patient with myelodysplastic syndrome. Int J Hematol 91(2):333\u2013335","journal-title":"Int J Hematol"},{"issue":"1","key":"1703_CR38","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1159\/000314961","volume":"124","author":"M Breccia","year":"2010","unstructured":"Breccia M, Loglisci G, Salaroli A, Cannella L, Santopietro M, Alimena G (2010) Deferasirox treatment interruption in a transfusion-requiring myelodysplastic patient led to loss of erythroid response. Acta Haematol 124(1):46\u201348","journal-title":"Acta Haematol"},{"issue":"1","key":"1703_CR39","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.1365-2141.1992.tb06411.x","volume":"80","author":"PD Jensen","year":"1992","unstructured":"Jensen PD, Jensen IM, Ellegaard J (1992) Desferrioxamine treatment reduces blood transfusion requirements in patients with myelodysplastic syndrome. Br J Haematol 80(1):121\u2013124","journal-title":"Br J Haematol"},{"issue":"2","key":"1703_CR40","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1159\/000158631","volume":"120","author":"E Messa","year":"2008","unstructured":"Messa E, Cilloni D, Messa F, Arruga F, Roetto A, Saglio G (2008) Deferasirox treatment improved the hemoglobin level and decreased transfusion requirements in four patients with the myelodysplastic syndrome and primary myelofibrosis. Acta Haematol 120(2):70\u201374","journal-title":"Acta Haematol"},{"key":"1703_CR41","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.3324\/haematol.2011.048546","volume":"97","author":"N Gattermann","year":"2012","unstructured":"Gattermann N, Finelli C, Della Porta M, Fenaux P, Stadler M, Guerci-Bresler A et al (2012) Hematologic responses with deferasirox therapy in transfusion-dependent myelodysplastic syndromes patients. Haematologica 97:1364\u20131371","journal-title":"Haematologica"},{"issue":"88","key":"1703_CR42","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.3324\/haematol.2010.024992","volume":"95","author":"H Ghoti","year":"2010","unstructured":"Ghoti H, Fibach E, Merkel D, Perez-Avraham G, Grisariu S, Rachmilewitz EA (2010) Changes in parameters of oxidative stress and free iron biomarkers during treatment with deferasirox in iron-overloaded patients with myelodysplastic syndromes. Haematologica 95(88):1433\u20131434","journal-title":"Haematologica"},{"issue":"1","key":"1703_CR43","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/j.1365-2141.2011.08587.x","volume":"153","author":"H Ghoti","year":"2011","unstructured":"Ghoti H, Fibach E, Westerman M, Gordana O, Ganz T, Rachmilewitz EA (2011) Increased serum hepcidin levels during treatment with deferasirox in iron-overloaded patients with myelodysplastic syndrome. Br J Haematol 153(1):118\u2013120","journal-title":"Br J Haematol"},{"issue":"8","key":"1703_CR44","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.3324\/haematol.2009.016824","volume":"95","author":"E Messa","year":"2010","unstructured":"Messa E, Carturan S, Maff\u00e8 C, Pautasso M, Bracco E, Roetto A et al (2010) Deferasirox is a powerful NF-kappaB inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging. Haematologica 95(8):1308\u20131316","journal-title":"Haematologica"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-013-1703-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-013-1703-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-013-1703-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T03:58:48Z","timestamp":1714967928000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-013-1703-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2,17]]},"references-count":44,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["1703"],"URL":"https:\/\/doi.org\/10.1007\/s00277-013-1703-7","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,2,17]]}}}